Neuroscience

Best-Selling Author Dr. Daniel Amen and Dr. Charles Fay Release New Book 'Raising Mentally Strong Kids'

Retrieved on: 
Thursday, March 7, 2024

Costa Mesa, California--(Newsfile Corp. - March 7, 2024) - #1 New York Times bestselling author and neuropsychiatrist Dr. Daniel Amen and child psychologist Dr. Charles Fay have teamed up to reveal what's missing from most parenting books.

Key Points: 
  • Costa Mesa, California--(Newsfile Corp. - March 7, 2024) - #1 New York Times bestselling author and neuropsychiatrist Dr. Daniel Amen and child psychologist Dr. Charles Fay have teamed up to reveal what's missing from most parenting books.
  • It's the fact that you need to address both the brain and the mind of your child (and yourself) to raise good and strong humans effectively.
  • Finally, evidence-based help is now available for overwhelmed parents who are trying their best but feel like they're falling short.
  • "In this book, I will provide you with a wealth of information to help you and your children develop strong brains," said Dr. Amen, co-author and double-board certified psychiatrist and founder of Amen Clinics and BrainMD .

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Retrieved on: 
Monday, March 11, 2024

The United States Patent and Trademark Office also recently granted US Patent 11,905,317 directed to immunogenic compositions of matter that are being developed for treating AD.

Key Points: 
  • The United States Patent and Trademark Office also recently granted US Patent 11,905,317 directed to immunogenic compositions of matter that are being developed for treating AD.
  • Protection for the immunogenic compositions of matter has also been obtained in Japan, Korea, India and Australia.
  • Further, patent applications were also recently allowed in the U.S. and Japan for two other Aβ targets.
  • “We are building a fortress of intellectual property protection around our novel approach to targeting toxic misfolded proteins to treat neurodegenerative diseases and these newly allowed patents validate that innovation in important geographies around the world,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024

ET

Key Points: 
  • ET
    THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended December 31, 2023 and provided an update on key corporate milestones.
  • “2023 was a pivotal year for Lexicon,” said Lonnel Coats, Lexicon’s chief executive officer.
  • Unless otherwise stated, all comparisons are for the fourth quarter and full year of 2023 compared to the fourth quarter and full year of 2022.
  • Revenues: Revenues for the fourth quarter and full year of 2023 were $0.7 million and $1.2 million, respectively, primarily from the commercialization of INPEFA.

Arvinas to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, March 4, 2024

NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:

Key Points: 
  • NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
    Leerink Partners Global Biopharma Conference on Tuesday, March 12.
  • Ron Peck, M.D., chief medical officer, and Randy Teel, Ph.D., interim chief financial officer, will participate in a fireside chat.
  • Ron Peck, M.D., chief medical officer, and Randy Teel, Ph.D., interim chief financial officer, will participate in investor 1x1 meetings.
  • Ian Taylor, Ph.D., chief scientific officer, and Angela Cacace, Ph.D., senior vice president of neuroscience and platform biology, will participate in a fireside chat.

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, February 28, 2024

Research and development expenses: In the fourth quarter of 2023, research and development expenses were $2.0 million, compared to $4.1 million in the fourth quarter of 2022.

Key Points: 
  • Research and development expenses: In the fourth quarter of 2023, research and development expenses were $2.0 million, compared to $4.1 million in the fourth quarter of 2022.
  • Selling, general, and administrative expenses: Selling, general, and administrative expenses for the fourth quarter of 2023 were $42.0 million compared to $14.1 million in the fourth quarter of 2022.
  • Amortization of intangible assets was $9.1 million in the fourth quarter of 2023), compared to $0.6 million in the fourth quarter of 2022.
  • Operating income: Operating income for the fourth quarter of 2023 was $41.7 million, compared to $30.8 million in the fourth quarter of 2022, representing an increase of approximately 35.4%.

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.

Key Points: 
  • SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
  • Research and Development Expenses: Research and development expenses were $69.5 million for the fourth quarter of 2023, compared to $44.0 million for the fourth quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $30.5 million for the fourth quarter of 2023 compared to $19.8 million for the fourth quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the fourth quarter of 2023, compared to a net loss of $57.5 million for the fourth quarter of 2022.

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Retrieved on: 
Tuesday, February 27, 2024

The NDA submission lacks data needed to establish that the change in negative symptoms of schizophrenia with roluperidone treatment was clinically meaningful.

Key Points: 
  • The NDA submission lacks data needed to establish that the change in negative symptoms of schizophrenia with roluperidone treatment was clinically meaningful.
  • The submitted safety database included an inadequate number of subjects exposed to roluperidone at the proposed dose (64 mg) for at least 12 months.
  • To address these deficiencies, the FDA stated that Minerva must submit at least one additional positive, adequate, and well-controlled study to support the safety and effectiveness of roluperidone for the treatment of negative symptoms.
  • “There is a critical need for a treatment for the negative symptoms of schizophrenia.

Red light therapy for neuro/cognitive benefits

Retrieved on: 
Friday, February 23, 2024

There is a simple and practical way – red light therapy to improve your brain function.

Key Points: 
  • There is a simple and practical way – red light therapy to improve your brain function.
  • Red light therapy (RLT), also known as low-level laser therapy (LLLT) or photobiomodulation (PBM), involves exposure to specific wavelengths of visible red and near-infrared light (660-850 nm) to stimulate biological processes in the body.
  • Red light therapy increases mitochondria function to promote balance between free radicals and antioxidants in the body.
  • Studies have highlighted red light therapy has a potential neuroprotective and disease-modifying role in treating Alzheimer's and Parkinson's patients.

Six Years Strong: Founder of Revitalist Kathryn Walker’s Continuous Leadership in Revolutionizing Mental Health Care

Retrieved on: 
Friday, February 23, 2024

The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.

Key Points: 
  • The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.
  • Kate NeuroPsych represents a groundbreaking approach to mental health care — offering 24/7 availability, personalized recommendations, and worldwide access — being designed by scientific leaders who are positively disrupting healthcare delivery at Revitalist and Sama Therapeutics .
  • Looking ahead, Kathryn envisions a future where psychedelics are normalized as essential tools in mental health care.
  • With each milestone she achieves, Kathryn Walker continues to redefine the boundaries of mental health care and inspire hope for a brighter, more compassionate future.

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Retrieved on: 
Thursday, February 22, 2024

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.

Key Points: 
  • CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.
  • ProMIS Neurosciences senior management will also conduct one-on-one meetings during the conference.
  • For more information or to schedule a meeting, please visit the conference page here or contact ProMIS Neurosciences Investor Relations.